In a report released today, Justin Walsh from JonesTrading maintained a Buy rating on Actinium Pharmaceuticals (ATNM - Research Report), with a price target of $24.00. The company's shares closed yesterday at $12.06.According to TipRanks, Walsh is an analyst with an average return of -30.7% and a 18.46% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, POINT Biopharma Global, and Plus Therapeutics.Currently, the analyst consensus on Actinium Pharmaceuticals is a Strong Buy with an average price target of $30.00, which is a 148.76% upside from current levels. In a report released on November 15, H.C.
https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-its-buy-rating-for-actinium-pharmaceuticals-atnm-2?utm_source=advfn.com&utm_medium=referral